NRG Therapeutics vs Genentech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised £50M ($67M) oversubscribed Series B (Sep 2025). First participants dosed in Phase 1 of NRG5051 (Jan 2026). Phase 1 readout expected end of 2026. Oral small molecules targeting mPTP in ALS and Parkinson's.
About
NRG Therapeutics develops first-in-class oral small molecules targeting the mitochondrial permeability transition pore (mPTP) — a protein complex whose aberrant opening triggers the cellular energy failure and neurodegeneration that underlies ALS (amyotrophic lateral sclerosis) and Parkinson's disease. The company raised £50 million ($67 million) in an oversubscribed Series B in September 2025, and dosed the first clinical trial participants for NRG5051 in January 2026, with Phase 1 readout expected by end of 2026.
Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.
About
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
NRG Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.